These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19711273)

  • 21. [Repeat transurethral resection for non-muscle invasive bladder cancer].
    Shen YJ; Ye DW; Yao XD; Zhang SL; Dai B; Zhu YP; Zhang HL; Zhu Y; Shi GH; Ma CG
    Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):725-7. PubMed ID: 19615201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
    Holmang S; Johansson SL
    J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificial intelligence for predicting recurrence-free probability of non-invasive high-grade urothelial bladder cell carcinoma.
    Cai T; Conti G; Nesi G; Lorenzini M; Mondaini N; Bartoletti R
    Oncol Rep; 2007 Oct; 18(4):959-64. PubMed ID: 17786360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of very large superficial bladder tumours: a 10-year experience.
    Gupta SK; Parr NJ
    Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
    Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS
    BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
    Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
    Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of "differentiated trandurethral resection" in the recurrence and progression of superficial bladder cancer].
    Angbein S; Guzmán S; Haecker A; Weib C; Michel MS; Alken P; Siegsmund M
    Arch Esp Urol; 2006; 59(1):25-30. PubMed ID: 16568690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy.
    Dwivedi US; Kumar A; Das SK; Trivedi S; Kumar M; Sunder S; Singh PB
    Urol Oncol; 2009; 27(5):514-9. PubMed ID: 18639472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
    BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?
    Volkmer BG; Schnoeller T; Kuefer R; Gust K; Finter F; Hautmann RE
    J Urol; 2009 Dec; 182(6):2632-7. PubMed ID: 19836794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urothelial papilloma of the bladder. Clinical and biologic implications.
    Cheng L; Darson M; Cheville JC; Neumann RM; Zincke H; Nehra A; Bostwick DG
    Cancer; 1999 Nov; 86(10):2098-101. PubMed ID: 10570437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.
    Canales BK; Anderson JK; Premoli J; Slaton JW
    J Urol; 2006 Jan; 175(1):74-7. PubMed ID: 16406874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age.
    Cho KS; Hwang TK; Kim BW; Yoon DK; Chang SG; Kim SJ; Park JY; Cheon J; Sung GT; Hong SJ;
    Urology; 2009 Apr; 73(4):828-32, 832.e1. PubMed ID: 19195693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic value of clinicopathologic factors in superficial bladder tumors: a retrospective analysis].
    Rammeh-Rommani S; Zermani R; Zouari B; Sfaxi M; Chabchoub A; Farah F; Kourda N; Ayed M; Ben Jilani S
    Tunis Med; 2005 Dec; 83(12):746-9. PubMed ID: 16450942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mid-term results of a program for the monitoring of superficial bladder tumors].
    Paez Borda A; Luján Galán M; Llanes González L; Gómez de Vicente JM; Berenguer Sánchez A
    Arch Esp Urol; 1999 Apr; 52(3):229-34; discussion 234-5. PubMed ID: 10371738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.